| Literature DB >> 14745155 |
Yukinori Nakagawa1, Uichi Ikeda, Masahiro Hirose, Satoshi Ubukata, Taka-Aki Katsuki, Yuichiro Kaminishi, Tsutomu Saito, Mitsugu Hironaka, Tohru Izumi, Kazuyuki Shimada.
Abstract
Primary cardiac malignant lymphoma is extremely rare and almost all patients die within weeks. Monoclonal CD20 antibody (rituximab) was administered to a patient with primary cardiac B-cell non-Hodgkin's lymphoma expressing a CD20 molecule. The results suggest that rituximab may be a safe and effective new therapy for primary cardiac B-cell lymphoma.Entities:
Mesh:
Substances:
Year: 2004 PMID: 14745155 DOI: 10.1253/circj.68.172
Source DB: PubMed Journal: Circ J ISSN: 1346-9843 Impact factor: 2.993